Sintx Technologies, Inc. (NASDAQ:SINT) Short Interest Up 20.3% in December

Sintx Technologies, Inc. (NASDAQ:SINT) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 206,724 shares, a growth of 20.3% from the December 15th total of 171,790 shares. Based on an average daily volume of 40,662 shares, the short-interest ratio is currently 5.1 days. Approximately 5.8% of the shares of the company are sold short. Approximately 5.8% of the shares of the company are sold short. Based on an average daily volume of 40,662 shares, the short-interest ratio is currently 5.1 days.

Insider Buying and Selling at Sintx Technologies

In other Sintx Technologies news, CIO Gregg R. Honigblum acquired 65,000 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were bought at an average price of $3.93 per share, with a total value of $255,450.00. Following the completion of the acquisition, the executive owned 139,000 shares in the company, valued at $546,270. This represents a 87.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have purchased 83,200 shares of company stock valued at $322,282. 4.08% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Virtus Wealth Solutions LLC purchased a new stake in Sintx Technologies during the 3rd quarter valued at approximately $388,000. Veracity Capital LLC lifted its holdings in shares of Sintx Technologies by 10.3% in the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after buying an additional 7,464 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Sintx Technologies by 33.5% during the second quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock worth $49,000 after acquiring an additional 3,848 shares during the last quarter. 18.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SINT has been the topic of several recent research reports. Ascendiant Capital Markets decreased their price target on shares of Sintx Technologies from $25.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, December 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Sintx Technologies in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Sintx Technologies from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Sintx Technologies presently has a consensus rating of “Hold” and a consensus target price of $16.00.

Sintx Technologies Trading Up 1.9%

Shares of SINT traded up $0.07 during trading hours on Monday, reaching $3.74. 7,489 shares of the stock traded hands, compared to its average volume of 39,489. Sintx Technologies has a 52-week low of $1.71 and a 52-week high of $7.36. The company’s 50-day moving average price is $3.67 and its two-hundred day moving average price is $3.63. The company has a market cap of $13.76 million, a P/E ratio of -0.66 and a beta of 0.65.

Sintx Technologies (NASDAQ:SINT) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($3.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.91). The business had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.20 million. Sintx Technologies had a negative return on equity of 218.25% and a negative net margin of 775.12%.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.